Cure Network Dolby Acceleration Partners LLC
San Francisco, United States · Founded 2021 · $3.0M raised
- Headquarters
- San Francisco, California
- Employees
- 1–10
- Founded
- 2021
- Business Model
- B2B
- Total Funding
- $3.0M
- Last Round
- $3.0M GrantJan 2023
- Rounds
- 1
About
Cure Network Dolby Acceleration Partners (CNDAP) is a therapeutics company developing small-molecule Nav1.1 enhancers to treat Alzheimer's disease. The company was formed through a partnership between Cure Network Ventures (Gladstone Institutes) and Dolby Acceleration Partners to advance translational neuroscience research. Its lead program targets restoration of brain network gamma oscillations disrupted in early Alzheimer's pathology.
Summary
Cure Network Dolby Acceleration Partners LLC is a Biotech company based in San Francisco, United States, founded in 2021. It has raised $3.0M in total across 1 round, most recently a $3.0M Grant round in Jan 2023. Investors include National Institutes of Health.
Sign up to view the funding chart
Create a free account — 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2023
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Specialty pharmaceutical company
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.